NICHOLE OROFINO: Open Payments
NPI 1396449286 · AUBURN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,528 in 191 payments from 14 companies in 2025. Trend: 2023 $375 · 2024 $1,996 · 2025 $2,528
Food & beverage: $2,528
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $435 |
| Teva Pharmaceuticals USA, Inc. | 42 | $430 |
| Alkermes, Inc. | 17 | $258 |
| Janssen Pharmaceuticals, Inc | 6 | $249 |
| Neurocrine BioSciences, Inc. | 31 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $223 |
| E.R. Squibb & Sons, L.L.C. | 22 | $220 |
| Vanda Pharmaceuticals Inc. | 9 | $214 |
| Otsuka America Pharmaceutical, Inc. | 11 | $150 |
| Lundbeck LLC | 2 | $44 |
Products named: VRAYLAR, ARISTADA, INGREZZA, CAPLYTA, COBENFY, AUSTEDO XR, UZEDY, SPRAVATO.
Industry payments across NY — which companies pay providers there.
